Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients?

Seizure. 2008 Jun;17(4):327-32. doi: 10.1016/j.seizure.2007.10.004. Epub 2007 Dec 3.

Abstract

Objective: To evaluate bodyweight gain during pregabalin therapy for epilepsy and the utility of a short counseling program to prevent this side effect.

Methods: Randomized controlled trial on the effects of extended versus standard patient counseling on the risk of bodyweight gain with 3- and 6-month follow-up including a consecutive sample of adult outpatients with epilepsy eligible for pregabalin add-on treatment (N=98).

Results: The seizure response rate was about 30%, the seizure freedom rate was 5% at the 6-month follow-up (intent-to-treat sample, N=98). The median bodyweight gain for the according-to-protocol sample (N=62) was 4.0 kg with no effect of extended counseling. Bodyweight gain was correlated with number of anticonvulsant drugs (r=.32, p<.05).

Conclusions: Pregabalin treatment is associated with a high risk for bodyweight gain which in part depends on total anticonvulsant drug load. This side effect cannot be prevented by extended patient counseling within a standard clinical setting.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Anticonvulsants / adverse effects*
  • Anticonvulsants / therapeutic use
  • Body Mass Index
  • Counseling
  • Diet
  • Epilepsy / complications*
  • Epilepsy / drug therapy
  • Exercise
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Pregabalin
  • Risk
  • Seizures / epidemiology
  • Seizures / prevention & control
  • Surveys and Questionnaires
  • Treatment Outcome
  • Weight Gain / drug effects*
  • gamma-Aminobutyric Acid / adverse effects
  • gamma-Aminobutyric Acid / analogs & derivatives*
  • gamma-Aminobutyric Acid / therapeutic use

Substances

  • Anticonvulsants
  • Pregabalin
  • gamma-Aminobutyric Acid